DOJ moves medical cannabis to Schedule III; biotech firms eye funding and IPOs amid banking and tax uncertainty.

Researchers at Johns Hopkins and UC San Diego used artificial intelligence to analyze comments in the public record ...

By Puyaan Singh and Christy Santhosh April 30 (Reuters) - Companies developing cannabis-based medicines say U.S. moves to ...

Acting Attorney General Todd Blanche signed an order Thursday reclassifying state-licensed marijuana as a less dangerous drug ...

The administration’s decision to relax federal regulations on medical marijuana comes with big tax breaks for many cannabis ...

The federal government’s reclassification of medical marijuana products as Schedule III drugs doesn’t federally legalize marijuana, but it might extend tax breaks to some cannabis businesses. ...

The Justice Department said the drug will now be listed on Schedule III, similar to some common prescription painkillers. The ...

Johns Hopkins research underscores the increased risks of combining cannabis edibles and alcohol—key for public health ...

Nearly 13 percent of Americans are using medications or marijuana to help them fall asleep at night, new federal data reveals ...

The move should make it easier for researchers to study the substance and give tax breaks to licensed medical marijuana ...

What do people mean when they talk about cannabis as an “exit drug”? This question may seem to fall outside the legal realm, but continued cannabis research is critical towards undercutting the ...